講演者

PLENARY KEYNOTES

  • K. Dane Wittrup, PhD, C.P. Dubbs Professor, Chemical Engineering and Biological Engineering; Associate Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT)
  • 2018 YOUNG SCIENTIST KEYNOTE
    Kipp Weiskopf, MD, PhD, Resident Physician, Internal Medicine, Brigham and Women’s Hospital

Engineering Stream
DISPLAY OF ANTIBODIES

  • Andrew M. Bradbury, PhD, MB BS, CSO, Specifica, Inc.
  • Frederic D. Bushman, PhD, Chair and Professor, Microbiology, University of Pennsylvania
  • Bryce Chackerian, PhD, Professor, Molecular Genetics and Microbiology, University of New Mexico School of Medicine
  • Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular
  • Stefan Ewert, PhD, Senior Investigator, NIBR Biologics Center, Novartis Pharma AG
  • Benjamin Hackel, PhD, Associate Professor, Chemical Engineering and Materials Science, University of Minnesota
  • Guy Hermans, PhD, CSO, Isogenica Ltd.
  • Mitchell Ho, PhD, Senior Investigator, National Cancer Institute, NIH
  • Joseph Jardine, PhD, Head, Antibody Discovery, Institute for Protein Innovation
  • David R. Liu, PhD, Richard Merkin Professor, Director, Merkin Institute of Transformative Technologies in Healthcare, Broad Institute Core Institute Member, Vice-Chair, Faculty, Director of the Chemical Biology and Therapeutic Sciences Program, Howard Hughes Medical Institute Investigator, Professor, Chemistry and Chemical Biology, Harvard University
  • Chuanbin Mao, PhD, Professor, Chemistry and Biochemistry, University of Oklahoma
  • Jennifer Maynard, PhD, Associate Professor, Chemical Engineering, University of Texas at Austin
  • James M. Olson, MD, PhD, Sarah Hughes Chair for Pediatric Oncology; Member, Fred Hutchinson Cancer Research Center; Attending Physician, Seattle Children’s Hospital; Professor of Pediatrics, University of Washington
  • Timothy Palzkill, PhD, Professor, Chair, Pharmacology and Chemical Biology, Baylor College of Medicine
  • Balaji M. Rao, PhD, Associate Professor, Chemical and Biomolecular Engineering, North Carolina State University
  • Aaron Sato, PhD, CSO, Antibody Center, LakePharma
  • Leila Sevigny, PhD, Senior Scientist, Sanofi Genzyme
  • Ernest Smith, CSO & Senior Vice President, Research, Vaccinex, Inc.
  • Greg M. Thurber, PhD, Assistant Professor, Chemical Engineering and Biomedical Engineering, University of Michigan
  • Benjamin Umlauf, PhD, Post-Doctoral Fellow, Chemical and Biological Engineering Department, University of Wisconsin

 

ENGEINEERING ANTIBODIES

  • Gregory Carven, PhD, Vice President, Antibody Discovery & Protein Sciences, Scholar Rock
  • Joel Cohen-Solal, PhD, Senior Research Scientist, Global Protein Sciences, AbbVie Bioresearch Center
  • Caroline Colley, PhD, Associate Director, Antibody Discovery and Protein Engineering, MedImmune, United Kingdom
  • Bruno Correia, PhD, Professor, Protein Design and Immunoengineering, EPFL Zurich, Switzerland
  • Pierre-Alain Girod, PhD, CSO, Selexis SA
  • David S. Johnson, PhD, CEO, GigaGen
  • JT Koerber, PhD, Scientist, Antibody Engineering, Genentech
  • Tim Larson, PhD, Marketing Specialist I, Marketing, Takara Bio USA
  • Chang-Han Lee, PhD, Postdoctoral Researcher, Georgiou Lab, The University of Texas at Austin
  • Greg Lazar, PhD, Director, Antibody Engineering, Genentech
  • Jonas Schaefer, PhD, Head, High-Throughput Binder Selection Facility, Biochemistry, University of Zurich, Switzerland
  • Eva-Maria Strauch, PhD, Research Assistant Professor, Biochemistry, University of Washington
  • Lioudmila Tchistiakova, PhD, Senior Director, Global Biotherapeutic Technologies, Pfizer
  • Danlin Yang, PhD, Scientist, Biotherapeutics Discovery, Boehringer Ingelheim
  • Andy Yeung, PhD, Associate Research Fellow, Rinat, Oncology R&D, Pfizer, Inc.

ENGINEERING BISPECIFIC ANTIBODIES

  • Edward A. Berger, PhD, Chief, Molecular Structure Section, Laboratory of Viral Diseases, NIAID, National Institutes of Health
  • Stanislas Blein, PhD, Senior Director, Head Antibody Engineering, Biologics Research, Glenmark Pharmaceuticals S.A.
  • Ulrich Brinkmann, PhD, Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Munich (RICM), Penzberg, Germany
  • Yvonne Y. Chen, PhD, Assistant Professor, Chemical and Biomolecular Engineering, University of California, Los Angeles
  • Mark Cobbold, MD, PhD, Cellular Immunotherapy Program, Center for Cancer Immunology, Massachusetts General Hospital; Member of the Faculty of Medicine, Harvard Medical School
  • John de Kruif, PhD, CTO, Merus NV
  • Nicolas Fischer, PhD, Head of Research, Novimmune
  • Yanwen Fu, PhD, Director, Antibody Technology and Chemical Biology, Sorrento Therapeutics
  • Stephen Gottschalk, MD, Chair, Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Research Hospital
  • Steven M. Larson, MD, FACNM, FACR, Donna and Benjamin M. Rosen Chair, Attending Molecular Imaging and Therapy Service, Radiology; Member and Lab Head, Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute; Professor, Radiology, Weill Cornell University Medical Center, Radioimmunotherapy and Theranostics, Ludwig Center
  • Jeffrey S. Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Hematology, Oncology and Transplantation, University of Minnesota
  • Amarendra Pegu, PhD, Staff Scientist, Laboratory of Virology, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH
  • Mitsuo Umetsu, PhD, Professor, Biomolecular Engineering, Graduate School of Engineering, Tohoku University
  • Thomas J. Van Blarcom, PhD, Associate Research Fellow, Oncology Research and Development, Pfizer, Inc., Rinat Laboratories
  • Maria Wendt, PhD, Head, Science, Biologics, Genedata
  • Chengbin Wu, PhD, CEO, EpimAb Biotherapeutics

Oncology Stream
ANTIBODIES FOR CANCER THERAPY

  • Ezio Bonvini, MD, Senior Vice President, Research & CSO, MacroGenics, Inc.
  • Paul B. Chapman, MD, Physician & Scientist, Memorial Sloan Kettering Cancer Center
  • Nai-Kong V. Cheung, MD, PhD, Head, Neuroblastoma Program; Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center
  • Bradley St. Croix, PhD, Senior Associate Scientist, Head, Tumor Angiogenesis Unit, Mouse Cancer Genetics Program, National Cancer Institute
  • Achim Doerner, PhD, Principal Scientist, Protein Engineering and Antibody Technologies, Merck KGaA Darmstadt, Germany
  • Gianpietro Dotti, MD, Lineberger Comprehensive Cancer Center Member, Professor, Microbiology and Immunology; Director, Lineberger Immunotherapy Program, University of North Carolina School of Medicine
  • Tim F. Greten, MD, Senior Investigator, GI Maligancy Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute
  • Mitchell Ho, PhD, Senior Investigator, National Cancer Institute, NIH
  • Patrick Mehlen, PhD, CEO Netris Pharma, Centre Leon Berard
  • Horacio G. Nastri, PhD, Senior Director, Antibody Biotherapeutics, Incyte Corporation
  • Junichi Nezu, PhD, Senior Specialist, Project & Lifecycle Management Unit, Chugai Pharmaceutical, Co., Ltd.
  • Patrick Ott, MD, PhD, Clinical Director, Melanoma Center; Clinical Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School
  • Ira H. Pastan, MD, Scientist, NIH NCI
  • Soldano Ferrone, MD, PhD, Surgical Oncology, Surgery, Massachusetts General Hospital
  • Kelli Ryan, PhD, Senior Scientist, Oncology Department, MedImmune
  • William R. Strohl, PhD, Owner and President, BiStro Biotech Consulting, LLC
  • Mark Throsby, PhD, CSO, Merus NV
  • Jennifer Wargo, MD, Melanoma Research, MD Anderson Cancer Center
  • Louis Weiner, MD, Professor, Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
  • Mingjie Xie, CEO, Rapid Novor, Inc.

ADVANCING BISPECIFIC ANTIBODIES AND COMBINATION THERAPY TO THE CLINIC

  • Julian Andreev, PhD, Senior Staff Scientist, Oncology and Angiogenesis, Regeneron Pharmaceuticals
  • Tara Arvedson, PhD, Director, Oncology Research, Amgen, Inc.
  • Carl Uli Bialucha, PhD, Oncology Biotherapeutics, Novartis Institutes for BioMedical Research, Inc.
  • Adrian Bot, MD, PhD, CSO, Kite Pharma, Inc.
  • Chien-Hsing Ken Chang, PhD, Vice President, Research & Development, Immunomedics, Inc.
  • Raphael Clynes, MD, PhD, Vice President, Translational Biology, Xencor, Inc.
  • Frank Comer, PhD, Scientist, MedImmune
  • Rakesh Dixit, PhD, DABT, Vice President, R&D, Global Head, Biologics Safety Assessment, Translational Sciences, MedImmune
  • David D. Ho, MD, Aaron Diamond AIDS Research Center, The Rockefeller University
  • Dirk Hose, PhD, Priv.-Doz. Dr. med. Dr. biol. hom., Head, Multiple Myeloma Research Laboratory, Universitaetsklinikum Heidelberg, Medizinische Klinik V
  • Ross La Motte-Mohs, PhD, Scientist III, Cell Biology and Immunology, MacroGenics, Inc.
  • G. Jonah Rainey, PhD, Executive Director, Head of Antibody Research, MabVax Therapeutics Holdings, Inc.
  • Leonard Seymour, PhD, Professor, Gene Therapy, Oncology, University of Oxford
  • Jacintha Shenton, PhD, Scientific Director, Biologics Toxicology, Janssen BioTherapeutics, Janssen R&D
  • Michael Tesar, PhD, Research Program Head, Research and Development, Affimed GmbH
  • Bob Valamehr, PhD, Vice President, Cancer Immunotherapy, Fate Therapeutics
  • Zhulun Wang, PhD, Executive Director, Biologics Department, Amgen

CLINICAL PROGRESS OF ANTIBODY-DRUG CONJUGATES

  • Adnan Abu-Yousif, PhD, Senior Scientist II, Discovery, Takeda
  • Donald A. Bergstrom, MD, PhD, CMO, Mersana Therapeutics
  • Anna Berkenblit, MD, MMSc, Vice President, CMO, ImmunoGen
  • Mahendra Deonarain, PhD, CEO & CSO, Antikor Biopharma Ltd.
  • David Goldenberg, ScD, MD, Founder and Former CSO, Immunomedics, Inc.
  • Trevor J. Hallam, PhD, CSO, Sutro Biopharma
  • Jay Harper, PhD, Senior Scientist, Oncology Research, MedImmune
  • Philip Howard, PhD, CSO, Spirogen; Senior Fellow, MedImmune
  • Gail Lewis Phillips, MSc, Senior Scientist, Translational Oncology, Genentech, Inc.
  • David (Shih-Yao) Lin, MD, PhD, CMO, AbGenomics, Inc.
  • Ed Reilly, PhD, Senior Research Fellow, Project Director, Oncology Discovery, AbbVie
  • Renu Singh Dhanikula, PhD, Senior Research Investigator, MAP, Bristol-Myers Squibb Company
  • Pamela Trail, Independent Consultant and Former Vice President, Oncology, Regeneron
  • Alessandra Micaela Villa, PhD, Head, Phage Display Technologies, Philochem AG
  • Jeff Wallin, PhD, Senior Director and Head, Biomarkers & Diagnostics, Seattle Genetics
  • William C. Zamboni, PharmD, PhD, Associate Professor and Director, Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Laboratory, UNC Lineberger Comprehensive Cancer Center

Immunotherapy Stream
IMPROVING IMMUNOTHERAPY EFFICACY AND SAFETY

  • Andrew Allen, MD, PhD, President & CEO, Gritstone Oncology, Inc.
  • Carlo Boutton, PhD, Director Technology & Information Management, Ablynx
  • Daniel Christ, PhD, Associate Professor, Director Centre for Targeted Therapy, Garvan Institute of Medical Research
  • Robert Hofmeister, PhD, CSO, Executive Leadership Team, TCR2 Therapeutics, Inc.
  • Alex Kelly, US Business Development Manager, Retrogenix
  • Saad J. Kenderian, Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine
  • Kathleen McGinness, PhD, Senior Director, Platform Technologies, Unum Therapeutics
  • Douglas Jolly, PhD, Executive Vice President, Research & Pharmaceutical Development, Research & Pharmaceutical Development, Tocagen Inc.
  • Maksim Mamonkin, PhD, Instructor, Center for Cell and Gene Therapy, Baylor College of Medicine
  • Daniel J. Powell Jr., PhD, Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania
  • Laszlo Radvanyi, PhD, Senior Vice President, Senior Scientific Advisor - Immunology, Immuno-Oncology, EMD Serono R&D Institute
  • Robert R. Salzler, PhD, Scientist, Bioanalytical & Biomarker Technologies, Regeneron Pharmaceuticals, Inc.
  • Steven Shamah, PhD, SVP, Head of Research, Obsidian
  • Naomi De Silva, PhD, Associate Director, Preclinical and Translational Science, Clinical, Sillajen Biotherapeutics, Inc.
  • Steven J. Swanson, PhD, Senior Vice President, Research, ImmunoCellular Therapeutics, Ltd.
  • Carston R. Wagner, PhD, Professor, Department of Medicinal Chemistry, University of Minnesota, and CSO, Tychon Bioscience, LLC
  • Claudia Wagner, PhD, Associate Director, TCR Discovery & Validation, Immatics

CAR Ts, TCRs AND TILs

  • J. Henri Bayle, PhD, Director of Molecular Biology, Research and Development, Bellicum Pharmaceuticals
  • Mark Bonyhadi, PhD, Head, Research, Juno Therapeutics
  • Adrian Bot, MD, PhD., Vice President, Translational Sciences, Kite, a Gilead Company
  • Mark Dudley, PhD, Senior Vice President, Bioprocessing & Development CMC, Technical Operations, Adaptimmune
  • Maria Fardis, PhD, CEO, Iovance
  • David Gilham, PhD, Vice President, Research, Celyad
  • Collin Hauskins, Research Scientist, Protein Sciences, Juno Therapeutics
  • Hans Klingemann, MD, PhD, Vice President, Research & Development, NantKwest, Inc.
  • Jeffrey S. Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota University of Minnesota
  • Molly Perkins, DPhil, Associate Director, Immunotherapy, bluebird bio
  • Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics Inc
  • Michel Sadelain, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
  • Andrew Sewell, PhD, Professor, Division of Infection and Immunity, Cardiff University School of Medicine
  • Bob Valamehr, PhD, Vice President, Cancer Immunotherapy, Fate Therapeutics

AGONIST IMMUNOTHERAPY TARGETS

  • Adam J. Adler, PhD, Professor, Immunology, University of Connecticut
  • Casey Ager, Graduate Research Assistant, Department of Immunology, University of Texas MD Anderson Cancer Center
  • Saso Cemerski, PhD, Principal Scientist, Merck Research Labs
  • Deborah H. Charych, PhD, Executive Director, Nektar Therapeutics
  • Adi Diab, PhD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
  • Peter Ellmark, PhD, Principal Scientist, R&D, Alligator Bioscience
  • Denise L. Faustman, MD, PhD, Director of Immunobiology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
  • Claudia Ferrara, PhD, Principal Scientist, Large Molecule Research, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich
  • Oliver Hill, PhD, Vice President, Molecular Biology, Apogenix
  • Debbie Law, DPhil, CSO, Jounce Therapeutics
  • Patrick Mayes, PhD, Executive Director, Head, IO Antibody Research, Incyte
  • Dafne Muller, PhD., Group Leader, Institute of Cell Biology and Immunology, University of Stuttgart
  • Taylor Schreiber, PhD, CSO, Research & Development, Shattuck Labs, Inc.
  • Harpreet Singh, President & CEO, Immatics US
  • Robert B. Stein, MD, PhD, Senior Advisor, R&D, Agenus, Inc.
  • Michael Yellin, MD, Vice President, Clinical Science, Celldex

Expression Stream
DIFFICULT TO EXPRESS PROTEINS

  • Randal Bass, PhD, Vice President, Just Biotech
  • Matthew A. Coleman, PhD, Senior Scientist, Lawrence Livermore National Laboratory
  • Hussain Dahodwala, PhD, Visiting Scientist, Vaccine Production Program, Vaccine Research Center, NIH
  • Martin Gamer, PhD, Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Haruki Hasegawa, PhD, Department of Therapeutic Discovery, Amgen
  • Akinori Hishiya, PhD, Principal Scientist, Biology, SOLA BioSciences
  • Azad Kumar, PhD, Viral Pathogenesis Laboratory, NIH/NIAID
  • David Laidlaw, CEO, Kuhner Shaker, Inc.
  • Kerstin Otte, PhD, Professor, Pharmaceutical Biotechnology, Biberach University
  • Harunur Rashid, PhD, Principal Scientist, Ambrx, Inc.
  • Paul Roepe, PhD, Professor, Chemistry, Biochemistry and Mol. Biology, Georgetown University
  • Gargi Roy, MSc, Scientist I, Antibody Discovery and Protein Engineering/Research, MedImmune LLC
  • Joop van den Heuvel, PhD, Department of Structure and Function of Proteins, Helmholtz Centre for Infection Research
  • Ernest Weber, PhD, Senior Scientist, Antibody Lead Discovery, Biologics Research, Bayer AG
  • Yi Xia, MD, Senior Scientific Researcher, Antibody Engineering, Genentech, Inc.
  • Alexei Yeliseev, PhD, Staff Scientist, Group Leader, LMBB, NIH, NIAAA

OPTIMIZING PROTEIN EXPRESSION

  • Nicola Beaucamp, PhD, Head, Process Research, Roche Innovation Center Munich, Pharma Research and Early Development, Roche Diagnostics GmbH
  • Imre Berger, PhD, Professor and Wellcome Trust Senior Investigator, Biochemistry, Biomedical Sciences and BrisSynBio Centre, University of Bristol
  • Jill Carton, PhD, Director, Biologics Discovery, Janssen Biotherapeutics, Janssen R&D
  • Colin Clarke, PhD, Principal Investigator, National Institute for Bioprocessing Research and Training (NIBRT)
  • Jan-Willem de Gier, PhD, Professor, Biochemistry and Biophysics, Stockholm University
  • William Gillette, PhD, Principal Scientist, Deputy Director, Protein Expression Laboratory, Leidos Biomedical Research, Inc.
  • Bernd Voedisch, PhD, Lab Head and Investigator III, NIBR Biologics Center, Novartis Institutes for Biomedical Research
  • Jamey Young, PhD, Associate Professor, Chemical and Biomolecular Engineering, Vanderbilt University
  • Jesse Rinehart, PhD, Associate Professor, Cellular & Molecular Physiology, Systems Biology Institute, Yale University School of Medicine
  • Robert Roth, PhD, Associate Principal Scientist, Innovative Medicines, Discovery Sciences, AstraZeneca
  • Anne Serdakowski London, PhD, Lab Head, Mid-Scale Mammalian Production, Therapeutic Protein Sciences, Novartis Institutes for Biomedical Research
  • Bernie Sweeney, Senior Group Leader, Mammalian Expression, UCB Pharma
  • Jorg Thommes, PhD, Senior Vice President, Pharmaceutical Sciences & Technology, Visterra, Inc.

PROTEIN EXPRESSION SYSTEM ENGINEERING

  • Abhishek Chatterjee, PhD, Assistant Professor, Chemistry, Boston College
  • Patricia L. Clark, PhD, Rev. John Cardinal O’Hara C.S.C. Professor, Biochemistry, University of Notre Dame
  • Michael Dyson, PhD, CTO, Antibody Engineering, IONTAS, Ltd.
  • Tobias Grosskopf, PhD, Scientist, Cell Culture Research, Roche Diagnostics GmbH
  • Olivier Henry, PhD, Associate Professor, Chemical Engineering, Ecole Polytechnique de Montreal
  • Michael Jewett, PhD, Charles Deering McCormick Professor of Teaching Excellence, and Associate Professor, Chemical and Biological Engineering, Northwestern University
  • Eric Kelsic, PhD, Staff Scientist, Wyss Institute, Harvard University
  • Minseung Kim, MSc, Scientist, Computer Science, UC Davis Genome Center, University of California, Davis
  • Nathan Lewis, Systems Biology & Cell Engineering, University of California, San Diego
  • Colton Lloyd, PhD Candidate, Bioengineering, University of California, San Diego
  • Shahram Misaghi, PhD, Senior Scientist, Early Stage Cell Culture, Genentech, Inc.
  • Dimitris Papamichail, PhD, Assistant Professor, Computer Science, The College of New Jersey
  • Lisa Alexandra Pieper, PhD, Postdoctoral Researcher, Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Anokha S. Ratnayake, PhD, Principal Scientist, Pfizer Global R&D Groton Labs
  • Lars Stockl, PhD, Senior Director, R&D, Glycotope GmbH

Analytical Stream
CHARACTERIZATION OF BIOTHERAPEUTICS

  • Michael Adamo, Senior Scientist, Bristol-Myers Squibb
  • Eric S. Alonzo, PhD, Scientist, Cellular Analytics, bluebird bio
  • Nathan Brown, PhD, Senior Scientist, AbbVie Bioresearch Center
  • Shan Chung, PhD, Principal Scientist and Group Leader, Genentech
  • Zhimei Du, PhD, Senior Principal Scientist, Merck & Company, Inc.
  • Stacey Helming, PhD, Scientist, Analytical Sciences, Regeneron Pharmaceuticals
  • Vibha Jawa, PhD, Director, Biologics and Vaccine Development, Merck
  • Xin Jiang, Product Manager, iCE, Marketing, ProteinSimple, a Bio-Techne brand
  • Jay Jones, Senior Research Associate, Seattle Genetics
  • Lynn Kamen, PhD, Scientist, Bioanalytical Sciences, Genentech
  • Alex Lazar, PhD, Director, Analytical and Pharmaceutical Sciences, ImmunoGen, Inc.
  • Kelvin Lee, PhD, Professor, Chemical & Biomolecular Engineering, University of Delaware
  • Zhenhong Li, PhD, Senior Director, Analytics, RegenxBio
  • Anthony Mire-Sluis, PhD, Head, Global Quality, AstraZeneca
  • Jennifer F. Nemeth, PhD, SCPM, Director, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
  • Da Ren, PhD, Principal Scientist, Amgen
  • Rich Rogers, PhD, Scientist, Just Biotherapeutics
  • Krishnan Sampath, PhD, Senior Director, Analytical and Drug Product Sciences, MacroGenics
  • Zhe Zhang, PhD, Senior Scientist, Integrated Biologics Profiling, Novartis

BIOPHYSICAL ANALYSIS OF BIOTHERAPEUTICS

  • George Bou-Assaf, PhD, Scientist, Technical Development, Biogen
  • Michael Brenowitz, PhD, Professor, Biochemistry and Molecular Pharmacology, Albert Einstein College of Medicine
  • Ralf Joe Carrillo, PhD, Senior Scientist, Physical Chemistry, AbbVie Bioresearch Center
  • John Champagne, Northeast Regional Manager, Wyatt Technology
  • Guodong Chen, PhD, Research Fellow, Bioanalytical and Discovery Analytical Sciences, Bristol-Myers Squibb
  • Mark T. Fisher, PhD, Professor, Biochemistry and Molecular Biology, University of Kansas Medical Center
  • Michael B. Goshe, PhD, Associate Professor, Molecular and Structural Biochemistry, North Carolina State University
  • David Hayes, PhD, Principal Scientist, Boehringer Ingelheim Pharmaceuticals, Inc.
  • Igor Kaltashov, PhD, Associate Professor, Chemistry, University of Massachusetts, Amherst
  • Hubert Kettenberger, PhD, Senior Principal Scientist, Protein Engineering, Roche Innovation Center Munich, Germany
  • Jennifer F. Nemeth, PhD, SCPM, Director, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
  • Deniz B. Temel, PhD, Scientist, Amgen
  • Kristopher Truncali, Scientist, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
  • William Weiss, PhD, Principal Research Scientist and Group Leader, Biophysical Characterization, Eli Lilly and Company

PROTEIN AGGREGATION AND STABILITY IN BIOPHARMACEUTICALS

  • Arun Alphonse Ignatius, PhD, Principal Scientist, Pfizer
  • David Brockwell, PhD, Associate Professor, School of Molecular and Cellular Biology, University of Leeds, United Kingdom
  • Didier Clenet, PhD, Research Scientist, Formulation & Stability, Sanofi Pasteur, Canada
  • Tom Crowley, PhD, Principal Scientist, Pharmaceutical R&D, Pfizer, Inc.
  • Zhimei Du, PhD, Head, Cell Line Development, Merck & Company, Inc.
  • Jason Fernandez, Scientist, Protein Pharmaceutical Development, Biogen
  • Raja Ghosh, PhD, Professor, Chemical Engineering, McMaster University, Canada
  • Christoph Grapentin, PhD, Postdoctoral Fellow, Pharmaceutical Development, F. Hoffmann-La Roche Ltd., Switzerland
  • Zhi (Jay) Guo, PhD, Senior Scientist, Global Protein Sciences, AbbVie Bioresearch Center
  • Theodore W. Randolph, PhD, Professor, Chemical & Biological Engineering, University of Colorado, Boulder
  • John Rech, Technology Manager, Particle Testing, Analytical Laboratory, West Pharmaceutical Services
  • Peter Schurtenberger, PhD, Professor, Physical Chemistry, Lund University, Sweden
  • Peter M. Tessier, PhD, Professor, Pharmaceutical Sciences and Chemical Engineering, University of Michigan
  • Neal Whitaker, PhD, Associate Researcher, Macromolecule and Vaccine Stabilization Center, Pharmaceutical Chemistry, The University of Kansas School of Pharmacy
  • Yingda Xu, PhD, Director, Protein Analytics, Adimab

Immunogenicity & Bioassays Stream
IMMUNOGENICITY CASE STUDIES AND CLINICAL MANAGEMENT

  • Steven Arkin, MD, Executive Director, Clinical Programs, Rare Disease Research Unit, Pfizer Worldwide R&D
  • Adam Cheifetz, MD, Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School
  • Jocelyne Demengeot, PhD, Principal Investigator, Instituto Gulbenkian de Ciencia, Portugal
  • Sandra Garces, MD, PhD, Senior Medical Advisor for Immunogenicity, GPS Medical and Benefit-Risk Management, Eli Lilly and Company
  • Ann Gils, PhD, Professor, Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium
  • George R. Gunn, III, PhD, Head, Immunogenicity and Clinical Immunology, Bioanalysis, Immunogenicity and Biomarkers, In Vitro/In Vivo Translation Platform, GlaxoSmithKline
  • Soumi Gupta, PhD, Director of Immunogenicity, Translational Sciences, BioMarin Pharmaceutical, Inc.
  • Katherine A. High, MD, Co-Founder, President and Head of R&D, Spark Therapeutics
  • M. Benjamin Hock, PhD, Director of Immunogenicity, BioMarin Pharmaceutical Inc.
  • Darshana Jani, Senior Manager, Global Assay Lead, Drug Development, Pfizer
  • Vibha Jawa, PhD, Director, Immunogenicity Strategy for Biologics and Vaccines, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc.
  • Priya Kishnani, MD, C.L. and Sue Chen Professor of Pediatrics, Division Chief, Medical Genetics, Duke University Medical Center
  • Chiyomi Kubo, PhD, DVM, Scientist, Research Division, Chugai Pharmaceutical Co., Ltd.
  • Kun Lu, PhD, Staff Scientist, Protein Biochemistry Group, Regeneron Pharmaceuticals, Inc.
  • Theo Rispens, PhD, PI Antibody Structure and Function, Sanquin
  • Amy S. Rosenberg, MD, Division Director, Office of Biotechnology Products, FDA/CDER
  • Jennifer Sims, Non-Clinical Expert, NDA Advisory Board, NDA Group
  • Karen Thudium, PhD, Head, Clinical Pharmacology Program, Cell and Gene Business Unit, Novartis

IMMUNOGENICITY ASSESSMENT AND REGULATORY APPROVAL OF BIOLOGICS

  • Tudor Arvinte, PhD, Professor, Biopharmaceutics, School of Pharmacy Geneva-Lausanne, University of Geneva and Therapeomic, Inc.
  • Bjorn Boll, PhD, Head, Particle Lab and Higher Order Structure Protein Analytics, Physical Chemical Analytics, Novartis Pharma AG
  • Steven Bowen, PhD, Immunogenicity Reviewer, OBP/OPQ/CDER, FDA
  • Shan Chung, PhD, Principal Scientist and Group Leader, Genentech, Inc.
  • Julio Delgado, MD, MS, CMO, ARUP Laboratories; Division Chief, Clinical Pathology, University of Utah School of Medicine; Associate Professor, Pathology, University of Utah
  • William Hallett, PhD, Product Quality & Immunogenicity Reviewer, CDER/OPQ/OBP, FDA
  • Marisa K. Joubert, PhD, Principal Scientist, Process Development, Amgen, Inc.
  • Lynn Kamen, PhD, Scientist, BioAnalytical Sciences, Genentech
  • Uma Kavita, PhD, Senior Research Investigator, Analytical and Bioanalytical Operations, Bristol-Myers Squibb
  • Bernard Maillere, PhD, Director, Research and Head of Immunochemistry Laboratory, Institute Frederic Joliot, SIMOPRO, CEA, University Paris-Saclay
  • Shraddha Rane, PhD, Postdoctoral Research Associate, Infection Immunity and Respiratory Diseases, The University of Manchester
  • Susan Richards, PhD, Presidential Scientific Fellow, Translational Medicine Early Development, Sanofi R&D
  • Theo Rispens, PhD, Immunopathology, Sanquin Research, Amsterdam, Netherlands
  • Zuben E. Sauna, PhD, Research Biologist & Principal Investigator, Haemostasis Branch, Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, FDA/CBER
  • Daniela Verthelyi, PhD, Chief, Laboratory of Immunology, Office of Biotechnology Products, Office of Pharmaceutical Quality, CDER
  • Zhandong Don Zhong, PhD, Associate Director, Teva Pharmaceuticals

OPTIMIZING BIOASSAYS FOR BIOLOGICS

  • Joseph Callahan, PhD, Technical Development Scientist, Genentech, Inc.
  • Shan Chung, PhD, Principal Scientist and Group Leader, Bioanalytical Sciences, Genenetech, Inc.
  • Gael Debauve, PhD, Associate Director, Bioassay Development, Analytical Sciences for Biologics, UCB
  • Jenny Hu, Scientist, PKDM, Amgen, Inc.
  • Natalia Kozhemyakina, PhD, Head, Bioassay Laboratory, Analytical Development Department, BIOCAD
  • Emily Lowe, PhD, Senior Scientist, Analytical Sciences, Kite Pharma, a Gilead Company
  • Areti Manola, Senior Principal Biostatistician, Non-Clinical Statistics, Manufacturing, Toxicology and Applied Statistical Sciences, Janssen, Pharmaceutical Companies of Johnson and Johnson
  • Kenneth R. Miller, PhD, Principal Scientist, Global Technical Operations, Analytical, AstraZeneca
  • Ashley Mullan, Scientist, Development, Analytical Sciences, MedImmune
  • Sandra Prior, PhD, Senior Scientist, Biotherapeutics, National Institute for Biological Standards and Control (NIBSC)
  • Perceval Sondag, Senior Manager, Statistics, PharmaLex
  • Dirk Usener, PhD, Head, Analytical Development 2, Bioanalytics, Sanofi
  • Steven Walfish, Principal Scientific Liaison, USP
  • Adrienne Wildt, PhD, Senior Scientist, Bioanalytical Science, Immunogen

Bioconjugates Stream
FUSION PROTEIN THERAPEUTICS

  • Ruben Boado, PhD, Vice President, Research & Discovery, ArmaGen Technologies, Inc.
  • Mathieu Cinier, PhD, CSO, Affilogic
  • Christina M. Coughlin, MD, PhD, CMO, Immunocore, LLC
  • Madiha Derouazi, PhD, CEO, Amal Therapeutics
  • Stephen D. Gillies, PhD, Founder & CEO, Provenance Biopharmaceuticals
  • Jeffrey Greve, PhD, Founder and CSO, Delinia, Inc. (Celgene)
  • Ravindra Kumar, PhD, Senior Vice President & CSO, Acceleron Pharma, Inc.
  • Ekkehard Moessner, PhD, Group Leader and Scientist, Protein Engineering, Roche Innovation Center Zurich
  • Nicola Pozzi, PhD, Assistant Professor, Biochemistry and Molecular Biology, Saint Louis University
  • Taylor Schreiber, MD, PhD, CSO and Co-Founder, Shattuck Labs, Inc.
  • Oliver Siefert, PhD, Scientist, Institute of Cell Biology and Immunology, University of Stuttgart
  • Patrik Stromberg, PhD, MBA, Senior Director, Head, Biomedical Science & Portfolio Innovation, Swedish Orphan Biovitrum AB (SOBI)
  • Li Tao, PhD, Research Fellow, Biologics Development, Bristol-Myers Squibb Company
  • Kenneth W. Walker, PhD, Director, Research, Therapeutic Discovery, Amgen, Inc.
  • Zhirui Wang, PhD, Assistant Professor, Surgery, Harvard Medical School; Senior Investigator/Head, Immunotoxin Laboratory, Center for Transplantation Sciences (CTS), Massachusetts General Hospital
  • Stefan Weigand, PhD, Global Head, Large Molecule Research, Roche Diagnostics GmbH
  • Sunny Zhou, PhD, Professor and Faculty Fellow, Chemistry and Barnett Institute, Northeastern University

ENGINEERING ANTIBODY-DRUG CONJUGATES

  • Roger Beerli, PhD, CSO, NBE-Therapeutics AG
  • Dennis Benjamin, PhD, Senior Vice President, Translational Research, Seattle Genetics
  • Ravi Chari, PhD, Vice President, Chemistry & Biochemistry, ImmunoGen, Inc.
  • Kurt Gehlsen, PhD, Vice President & CSO, Therapeutics, Research Corporation Technologies, Inc.
  • Yelena Kovtun, Associate Director, Pipeline R&D, ImmunoGen, Inc.
  • Chawita Netirojjanakul, PhD, Scientist, Therapeutic Discovery, Amgen
  • Andreas Pahl, PhD, CSO, Heidelberg Pharma
  • Obadiah J. Plante, PhD, Director, Research, Visterra, Inc.
  • Jan E. Schnitzer, MD, Director, Professor, Cellular & Molecular Biology, Proteogenomics Research Institute for Systems Medicine (PRISM)
  • Ginette Serrero, PhD, CEO, A&G Pharmaceutical, Inc.
  • Philipp R. Spycher, PhD, PSI Founder Fellow, Center for Radiopharmaceutical Sciences, Paul Scherrer Institut
  • Breanna S. Vollmar, PhD, Senior Scientific Researcher, Protein Chemistry, Genentech, Inc.
  • Alain Wagner, PhD, Research Director, Biofunctional Chemistry, Faculty of Pharmacy, University of Strasbourg
  • Robert Yongxin Zhao, PhD, CEO, Hangzhou DAC Biotech Co., Ltd.

CLINICAL PROGRESS OF ANTIBODY-DRUG CONJUGATES

  • Adnan Abu-Yousif, PhD, Senior Scientist II, Discovery, Takeda
  • Donald A. Bergstrom, MD, PhD, CMO, Mersana Therapeutics
  • Anna Berkenblit, MD, MMSc, Vice President, CMO, ImmunoGen
  • Mahendra Deonarain, PhD, CEO & CSO, Antikor Biopharma Ltd.
  • David Goldenberg, ScD, MD, Founder and Former CSO, Immunomedics, Inc.
  • Trevor J. Hallam, PhD, CSO, Sutro Biopharma
  • Jay Harper, PhD, Senior Scientist, Oncology Research, MedImmune
  • Philip Howard, PhD, CSO, Spirogen; Senior Fellow, MedImmune
  • Gail Lewis Phillips, MSc, Senior Scientist, Translational Oncology, Genentech, Inc.
  • David (Shih-Yao) Lin, MD, PhD, CMO, AbGenomics, Inc.
  • Ed Reilly, PhD, Senior Research Fellow, Project Director, Oncology Discovery, AbbVie
  • Renu Singh Dhanikula, PhD, Senior Research Investigator, MAP, Bristol-Myers Squibb Company
  • Pamela Trail, Independent Consultant and Former Vice President, Oncology, Regeneron
  • Alessandra Micaela Villa, PhD, Head, Phage Display Technologies, Philochem AG
  • Jeff Wallin, PhD, Senior Director and Head, Biomarkers & Diagnostics, Seattle Genetics
  • William C. Zamboni, PharmD, PhD, Associate Professor and Director, Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Laboratory, UNC Lineberger Comprehensive Cancer Center

Therapeutics & Technologies Stream
EMERGING INDICATIONS FOR THERAPEUTIC ANTIBODIES

  • Dan Allison, PhD, Senior Director, Antibody Technologies, Alder Biopharmaceuticals
  • Robin Barbour, Head, Antibody and Assay Development, Research, Prothena Biosciences
  • Gabriela Dos Santos Cruz De Matos, PhD, Senior Scientific Investigator, Biopharm Molecular Discovery, GlaxoSmithKline, United Kingdom
  • Joachim Feldwisch, PhD, Director, Preclinical Development, Affibody AB, Sweden
  • Robert P. Giugliano, MD, Senior Investigator, TIMI Study Group, Staff Physician, Cardiovascular Medicine, Brigham and Women’s Hospital; Associate Professor, Medicine, Harvard Medical School
  • Gregory C. Ippolito, PhD, Research Assistant Professor, Molecular Biosciences, Georgiou Lab, The University of Texas at Austin
  • Leonard Kaczmarek, PhD, Professor, Pharmacology, Cellular and Molecular Physiology, Yale University School of Medicine
  • Hikaru Koga, Researcher, Biologics Discovery Department, Chugai Pharmaceutical Co., Ltd., Japan
  • Thomas Mikita, PhD, Director, Centers for Therapeutic Innovation, Pfizer, Inc.
  • Janice M. Reichert, PhD, Executive Director, The Antibody Society
  • Luke Robinson, PhD, Associate Director, Research, Visterra, Inc.
  • Dan Sexton, PhD, Director, Pharmacology, Shire
  • Devin Sok, PhD, Director, Antibody Discovery and Development, International AIDS Vaccine Initiative (IAVI)
  • Christine Tkaczyk, PhD, Senior Scientist, Infectious Diseases/Vaccines, MedImmune
  • Tianlei Ying, PhD, Head, Antibody Engineering and Drug Discovery Group, School of Basic Medical Science, Fudan University, China
  • Ali Zarrin, PhD, Senior Scientist, Immunology and Antibody Engineering, Genentech

CRISPR FOR GENOME ENGINEERING

  • Aaron T. Cheng, PhD, Head, PTS Discovery Genome Editing, Protein Cellular and Structural Sciences, R&D Platform Technology & Science, GlaxoSmithKline
  • Patrick Collins, PhD, Senior Scientist, Genome Analysis Unit, Amgen
  • Michael Dyson, PhD, CTO, Antibody Engineering, IONTAS, Ltd.
  • John Feder, PhD, Associate Director, Genome Biology, Bristol-Myers Squibb
  • Gus Frangou, PhD, Fellow, Molecular and Integrative Physiological Sciences, Harvard TH Chan School of Public Health
  • Judith Greengard, PhD, RAC, Director, Bioanalytics and Development, Sangamo Therapeutics
  • Tony Ho, MD, Executive Vice President, Head of R&D, CRISPR Therapeutics
  • Fuguo Jiang, PhD, Postdoc Fellow, Molecular and Cell Biology, University of California, Berkeley
  • Colin A. Johnson, PhD, Professor of Medical & Molecular Genetics, Section of Ophthalmology and Neurosciences, Leeds Institute of Molecular Medicine
  • Julia Joung, Graduate Student. Biological Engineering, MIT
  • Kristian Laursen, PhD, Professor, Pharmacology, Cornell University
  • Chengzu Long, PhD, Asst Professor, Department of Medicine, New York University
  • Bettie Osuna, PhD, Graduate Student, Bondy-Denomy Lab, University of California, San Francisco

NANOTECHNOLGY IN MEDICINE

  • Itai Benhar, PhD, Professor, Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel Aviv University
  • Michelle Bradbury, MD, PhD, Director, Intraoperative Imaging, Radiology, Memorial Sloan Kettering Cancer Center
  • Jose Luis Corchero Nieto, PhD, Senior Scientist, Nanobiotechnology Group, CIBER-BBN, Institute of Biotechnology and Biomedicine, Universitat Autonoma de Barcelona
  • Brian T. Cunningham, PhD, Willett Professor of Engineering, Director, Micro and Nanotech Lab, Electrical and Computer Engineering, University of Illinois at Urbana -Champaign
  • Daryl Drummond, PhD, Head of Research, Merrimack Pharmaceuticals
  • Ali Fattom, PhD, Senior Vice President, Vaccine R&D, NanoBio Corp.
  • Seungpyo Hong, PhD, Professor, Pharmaceutics, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison
  • Taeghwan Hyeon, PhD, SNU Distinguished Professor, School of Chemical and Biological Engineering, Seoul National University
  • Kei Kishimoto, PhD, CSO, Selecta Biosciences
  • Paul Millner, PhD, Professor of Bionanotechnology, School of Biomedical Sciences, University of Leeds
  • Hayat Onyuksel, PhD, Professor, Biopharmaceutical Sciences, University of Illinois
  • Jianghong Rao, PhD, Professor, Radiology and Chemistry (courtesy), Molecular Imaging Program, Cancer Biology and Biophysics Programs, Stanford University
  • Jan E. Schnitzer, MD, Director, Professor of Cellular & Molecular Biology, Proteogenomics Research Institute for Systems Medicine (PRISM)
  • Jinjun Shi, PhD, Assistant Professor, Center for Nanomedicine, Brigham and Women’s Hospital, Harvard Medical School
  • Matthias Stephan, MD, PhD, Associate Member, Fred Hutchinson Cancer Research Center, Associate Professor, University of Washington

TRAINING SEMINARS

  • David Bramhill, PhD, Founder, Bramhill Biological Consulting, LLC
  • Christopher Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
  • Masha Fridkis-Hareli, MSc, PhD, Founder and President, ATR, LLC
  • Simon Friedensohn, MSc, Research Assistant; Biosystems Science and Engineering, ETH Zurich, Switzerland
  • Arno Kromminga, PhD, Member, European Immunogenicity Platform, Senior Vice President and European CSO, BioAgilytix
  • Sheila G. Magil, PhD, Senior Consultant, BioProcess Technology Consultants, Inc.
  • Enkelejda Miho, Ph.D., Research Assistant II, Biosystems Science and Engineering; Pioneer Innovation & Entrepreneurship Lab, ETH Zurich, Switzerland
  • Tatiana Novobrantseva, PhD, Co-Founder, Head of Research and Development, Verseau Therapeutics
  • Frank J. Riske, PhD, Senior Consultant, BioProcess Technology Consultants, Inc.
  • Perceval Sondag, Senior Manager, Statistics, PharmaLex
  • Traian Sulea, PhD, Senior Research Officer, Human Health Therapeutics, National Research Council Canada

SHORT COURSE INSTRUCTORS

  • Tara Arvedson, PhD, Director, Oncology Research, Amgen
  • Glareh Azadi, PhD, Senior Scientist, Translational PKPD, Merck Research Laboratories
  • Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.
  • Christine P. Chan, PhD, Principal Scientist, Global Manufacturing Science & Technology, Sanofi
  • Kelly Doering, PhD., DMPK Business Manager, Pharmaceutical Business, Waters
  • Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School
  • Isabel Figueroa, PhD, Scientist, PTPK, Genentech, Inc.
  • Dennis Ford, Founder and CEO, Life Science Nation
  • Ben Hock, PhD, Director, Immunogenicity, BioMarin Pharmaceuticals
  • Darshana Jani, MS, Senior Manager, Pfizer, Inc.
  • Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College
  • Veronica Juan, PhD, Principal Scientist, Protein Sciences, Merck Research Labs
  • Scott L. Klakamp, PhD, Vice President of Chemistry and Biochemistry, Bioptix
  • Seema Kumar, PhD, Associate Director, Quantitative Pharmacology & Drug Disposition (QPD), R&D Global Early Development (GED), EMD Serono, a business of Merck KGaA, Darmstadt, Germany
  • Christian Kunz, PhD., Associate Director, MorphoSys AG
  • Vinodh B. Kurella, PhD, Senior Scientist, Protein Engineering, Immuno-Oncology Division, Intrexon Corp.
  • Paul Rhyne, PhD., VP, Biological Development Services
  • Jonas Schaefer, PhD, Head, High-Throughput Binder Selection Facility, Biochemistry, University of Zurich
  • Ravi Shankar Singh, PhD, Associate Director, Clinical Pharmacology, Pfizer
  • Mohammad Tabrizi, PhD, Director Biologics Discovery, Merck Research Laboratories Palo Alto
  • Magdalena Tary-Lehmann, MD, PhD, CSO, Cellular Technology Limited (CTL); Adjunct Associate Professor of Pathology, Case Western Reserve University (CWRU)
Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

カタログダウンロード
カタログ(PDF)